Study is First to Demonstrate Increased Long-Term Survival Following Cardiac Arrest Using New CPR Devices
Results published in prestigious, global medical journal
A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in Wednesday’s online edition of The Lancet, one of the world’s leading medical journals.
The study shows that cardiopulmonary resuscitation (CPR) performed using the combination of two new CPR devices, the ResQPump® and ResQPOD®, gave patients who suffer out of hospital cardiac arrest a 53 percent better chance of survival, as compared with standard CPR.
Dr. Robert Domeier, EMS medical director for the Washtenaw / Livingston Medical Control Authority and emergency physician at St. Joseph Mercy Ann Arbor was the lead investigator for this study locally. He worked with researchers at St. Joseph Mercy Ann Arbor, Huron Valley Ambulance, Livingston County EMS, 27 fire-based EMS agencies, and other local hospitals; along with six other study sites in the United States to conduct the study.
"We’re very excited that survival rates in this area improved dramatically as a result of the study. It’s a testament not only to the value of the devices but to the dedication of our systems’ EMS providers,” said Domeier. “The goal of resuscitation during cardiac arrest is long-term survival with preservation of brain function. Previously we have focused on bystander CPR and defibrillation. This new, effective intervention is potentially the most significant advancement in the treatment of cardiac arrest since defibrillation.”
Conducted between 2005 and July 2010, the trial compared survival rates of a control group of 813 cardiac arrest patients receiving standard CPR to an intervention group of 840 patients receiving Compression/Decompression CPR (ACD CPR), performed using the ResQPump and the ResQPOD. The study reported a 53 percent improvement in survival-to-hospital-discharge rate with good neurologic function. Overall survival improved from 5.8 percent to 8.9 percent.
The study was funded, in part, by a grant from the National Institutes of Health and was sponsored by Advanced Circulatory Systems, Inc. Based on these positive study results; the company is seeking approval from the Food and Drug Administration (FDA) to market the ResQPump/ResQPOD device combination for CPR in patients suffering a cardiac arrest.
The ResQPump® is a hand-held, active compression decompression (ACD) CPR device placed in the same position on the sternum as the hands and enabling rescuers to perform similar chest compressions as in conventional CPR. Instead of allowing the chest wall to recoil passively, however, rescuers pull up on the ResQPump’s handle with its suction cup. This provides active decompression of the chest, promotes optimal chest wall recoil and creates a negative intrathoracic pressure (vacuum) that helps return blood to the heart. The handle contains a force gauge and metronome that guide compression depth, recoil and rate. The ResQPump is identical to the CardioPump®, an ACD CPR device available for sale outside the US.
The ResQPOD® is an impedance threshold device (ITD) that selectively prevents unnecessary respiratory gases from entering the chest during the chest wall recoil phase of CPR. It is attached within the ventilation circuit between the airway device and the ventilation source. By selectively restricting airflow during CPR, the device creates a small but important negative pressure (vacuum) in the chest that has been shown in numerous human and animal clinical trials to increase blood flow back to the patient’s heart during CPR.
For additional questions about the study, please contact Jennifer Fowler at 734-712-8900.